Navigation Links
Dr. Michael Johnson, CEO and Co-founder of Visikol, Invited to Speak with Governor Murphy on Behalf of the Science, Innovation, and Technology Commission Bill

Visikol began its journey in late 2012 as an idea at Rutgers University by Visikol Co-Founder Dr. Thomas Villani. Through support from advisors, mentors, the Rutgers Technology Transfer team and Foundation Venture Capital Group, Visikol Inc was launched a few years later.

Visikol’s path from an idea to a successful biotech company has been a circuitous path but was due in large part to the resources at Rutgers University, New Jersey-based investors and an ecosystem in New Jersey of mentors, advisors and experts. Since taking office, Governor Phil Murphy has been a strong advocate for building the New Jersey science, innovation and technology ecosystem by bringing together academic institutions and making it easier to bring an idea to life in the state. This focus is in response to many technology companies leaving the state or startups pursuing other states to grow their businesses in such as New York, Massachusetts or California.

To support this effort, Governor Murphy recently announced the launch of the initiative through which anyone can easily access the state’s academic experts. The centralization of this information in one database allows anyone to quickly find a technical expert in almost any field that can help them bring their idea to life. This database includes researchers and scientists from Princeton University, New Jersey Institute of Technology (NJIT), Stevens Institute of Technology, Rutgers University and Rowan University (Montclair State University will be joining the list soon).

To further these efforts, on August 15th, Governor Murphy held a press conference at the Commercialization Center for Innovative Technologies in North Brunswick, NJ to announce the re-instatement of the state’s Commission on Science, Innovation and Technology. The commission will be reinstated and will be provided with $1 million in funding to launch initiatives aimed at re-establishing innovation in NJ.

As the CEO of a company which began as an idea at Rutgers University and has matured into a profitable biotech business, Dr. Michael Johnson from Visikol was asked to speak at this press conference which was held a few hundred yards away from where the idea for Visikol was conceived.

After an introduction from James Barrood, President of the NJ Tech Council, The Governor started the press conference by stressing the importance of fostering innovative and scientific companies and his major campaign goal of re-establishing New Jersey as the leading state for up and coming innovative companies like Visikol. The Governor then introduced Dr. Michael Johnson who spoke on behalf of Visikol and described their journey from Rutgers to maturing an innovative business within the state.

Dr. Johnson began his speech by describing Visikol and their mission to accelerate drug discovery through the use of the machine learning, computer vision and advanced drug discovery tools that it has developed. Dr. Johnson explained that “there is currently a myth in the entrepreneurial community wherein a founder pulls themselves up by the bootstraps without the help of anyone else and wills their idea into existence.” However, it was described how this narrative is truly a myth and that launching a company is incredibly challenging and requires an ecosystem of experts, investors and resources. Visikol was only able to transform form an idea to a profitable and successful company through the help of New Jersey-based investors, the NJ EDA, Rutgers University, Foundation Venture Capital Group and a large group of advisors and mentors.

For these reasons, Dr. Johnson expressed a sincere interest in the Governor’s efforts to launch and to re-establish the Commission on Science, Innovation and Technology. Dr. Johnson explained how founders of a company seldom have all of the answers and by bringing together all of the experts in the state in one database it allows founders to much more easily find an expert to assist them with their endeavor.

Click here for full press conference video.

About Visikol
Visikol is focused on accelerating drug discovery through quantitative histopathology and using their patented Visikol HISTO tissue clearing technology to transform tissues into three dimensional data sets that can be mined for actionable insights. When paired with fluorescent labeling and 3D microscopy, Visikol® HISTO™ allows tissues such as 3D cell culture models or whole tissues to be imaged in their entirety in 3D. Visikol has leveraged this technology to launch 3Screen™ which is a high-throughput 3D imaging platform capable of transforming tissues into 3D data sets and answering complex biological questions. The addition of 3D histological information to the drug discovery workflow allows for complex features such as vasculature networks to be quantitatively analyzed in 3D or for the penetration kinetics of antibodies into tumor models to be understood. The company currently offers 3Screen™ as a service to pharmaceutical/biotech companies and is continually focused on improving the platform as well as building out a suite of standardized assays. In addition to this service offering, Visikol also sells various tissue clearing reagents and kits for academic researchers that are interested in adopting the approach into their own workflows. For more information about Visikol® or 3Screen™, please visit our website at

For additional assistance, journalists, investors and analysts may contact:

Dr. Michael Johnson
Chief Executive Officer

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related biology technology :

1. Periodontist Michael Hoge, DMD; MS of Precision Periodontics and Implant Dentistry Now Offers LANAP Laser Treatment for Gum Disease
2. Former VP of Clinical Pharmacology at Nektar Therapeutics, Michael A. Eldon, PhD, FCP, Joins NDA Partners as Expert Consultant
3. Slone Partners Hosts Precision Medicine Event Led by Michael Pellini, MD with Panelists Troy Cox, Barbara Weber, MD and Roman Yelensky, PhD
4. Inhibikase Awarded $433,000 from The Michael J. Fox Foundation to Advance Development of Kinase Inhibitor Treatment for Parkinsons Disease
5. Dr. Michael A. Pfaller of T2 Biosystems to Discuss the Vital Role of Transformative Diagnostics in Optimizing Antimicrobial Stewardship in New Webinar
6. Arizona Hand Surgeon Dr. Michael Fitzmaurice Double Board-Certified in Surgery and Surgery of the Hand
7. Recruitment Process Outsourcing (RPO) Market Heats Up Faster as Accolo Hires RPO Heavyweight Michael Palmer
8. Bantam Pharmaceutical Appoints Dr. Michael Luther President and CEO
9. Capital Edge Consulting expands CPSR Consulting Practice with addition of team member Michael Carter
10. Biocept CEO Michael W. Nall to Present at the Personalized Medicine World Conference
11. Distinguished Gastroenterologist Dr. Michael Docktor, Joins uBiome Advisory Board
Post Your Comments:
(Date:6/18/2019)... ... ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell ... of a person’s own adipose-derived stem cells to treat their osteoarthritis. The first clinical ... IND is the first of several planned clinical trials which will enable qualified PSC-enrolled ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... add 80 of its scientific journals to DeepDyve’s rental service for peer-reviewed journals. ... continually expanding library of more than 20 million articles, sourced from more than ...
(Date:6/6/2019)... Calif. (PRWEB) , ... June 05, 2019 , ... ... biotechnology and medical device industries, announced today that they will be receiving 3 awards ... San Diego, CA. WCCT received 2 awards in the categories of overall Quality and ...
(Date:5/31/2019)... ... May 30, 2019 , ... Object ... announce the strategic acquisition of Metabiologics, Inc., a globally recognized leader in the ... ownership and commercialization rights to a full spectrum of botulinum neurotoxins, as well ...
Breaking Biology Technology:
(Date:6/4/2019)... ... ... Lajollacooks4u is delighted to announce it has been named as one of ... only to businesses that have achieved consistently outstanding traveler reviews on TripAdvisor, as well ... qualify for the Certificate of Excellence –- an award that only 10 percent of ...
(Date:5/31/2019)... (PRWEB) , ... May 30, 2019 , ... ... genetics testing company, and Mayo Clinic, have documented significant differences in the prevalence ... racial and ethnic populations compared to non-Hispanic White women. Results will be presented ...
(Date:5/26/2019)... ... May 24, 2019 , ... Zolgensma (Novartis, AveXis), an AAV-delivered gene therapy used ... use in the United States by the Food and Drug Administration today. ... inherited genetic disorders in the United States and the second-ever approved treatment for SMA. ...
Breaking Biology News(10 mins):